Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I

摘要

Background: Eslicarbazepine acetate (ESL) is an anticonvulsant approved as an adjunctive therapy in adults with partial onset seizures.